

WHAT IS CLAIMED IS:

1. A method of treating an individual having irritable bowel syndrome or a related disorder, comprising the step of:

5 administering to said individual a pharmacologically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects.

10

2. The method of claim 1, wherein said luminally active anti-inflammatory compound is a steroid.

15

3. The method of claim 2, wherein said steroid is beclomethasone.

20

4. The method of claim 3, wherein said beclomethasone is beclomethasone dipropionate.

5. The method of claim 4, wherein said beclomethasone dipropionate is orBec™.

5

6. The method of claim 4, wherein said orBec™ is administered in a dose of from about 0.1 mg/kg to about 20 mg/kg.

10

7. The method of claim 1, wherein said anti-inflammatory compound is budesonide, clobetasol, halbetalol, fluocinonide, halcinonide, betamethasone, mometasone, alclometasone, triamcinolone or fluocinolone.

15

8. The method of claim 1, wherein said immunosuppressive compound is selected from the group consisting of methotrexate, azothioprine, 6 mercaptopurine, cyclosporine and 20 FK506.

9. The method of claim 1, wherein said a related disorder is non-ulcer dyspepsia or noncardiac chest pain.

5

10. A method of inhibiting the onset of symptoms of irritable bowel syndrome or a related disorder in an individual in need of such treatment, comprising the step of:

10 administering to the individual a prophylactically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects.

15 11. The method of claim 10, wherein said luminally active anti-inflammatory compound is a steroid.

20 12. The method of claim 11, wherein said steroid is beclomethasone.

13. The method of claim 12, wherein said beclomethasone is beclomethasone dipropionate.

5

14. The method of claim 13, wherein said beclomethasone dipropionate is orBec™.

10 15. The method of claim 14, wherein said orBec™ is administered in a dose of from about 0.1 mg/kg to about 20 mg/kg.

16. The method of claim 10, wherein said luminally 15 active anti-inflammatory compound is budesonide.

17. The method of claim 10, wherein said immunosuppressive compound is methotrexate, azothiorpine, 6 20 mercaptopurine, cyclosporine and FK506.

18. The method of claim 1, wherein said a related disorder is non-ulcer dyspepsia or noncardiac chest pain.